Tdap
Tetanus, Diphtheria, acellular Pertussis Vaccine
Platform: Toxoid + acellular subunit
Combination vaccine that protects against tetanus, diphtheria, and whooping cough (pertussis), including maternal immunization for newborn protection.
Immunology Sections
Curated section analysis in progress
Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.
Wikipedia Overview
Full article ↗
The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis, and tetanus (lockjaw). The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.
PubMed Literature
Search PubMed ↗No PubMed results retrieved.
Semantic Scholar
Search S2 ↗Aapo Knuutila, A. Barkoff, Lauri Ivaska et al. · 2023
18 citationsInvestigating the maternal immune response to IP and the effect of IP and pre-existing antibodies on infants’ primary vaccine responses in an open-label, non-randomized trial concluded that IP resulted in significantly higher concentrations of antibodies in infants up to three months of age, but was associated with blunting of various infants' vaccine responses.
R. Koepke, J. Eickhoff, R. Ayele et al. · 2014
147 citationsBoostrix was more effective than Adacel in preventing pertussis in the cohort of Wisconsin residents born during 1998-2000, but these findings may not be generalizable to adolescent cohorts that received different diphtheria-tetanus-acellular pertussi vaccines (DTaP) during childhood and should be further examined in studies that include childhood DTaP history.
Changhong Jiang, Laquita Whitmore-Sisco, A. Gaur et al. · 2018
15 citationsOverall vaccination rates increased to 90% over 15 months, a rate that has been sustained by systematically assessing new employees' vaccination status and vaccinating those without documentation of previous Tdap vaccination.
Susana Portillo, Jennifer J. Oshinsky, Margaret Williams et al. · 2024
7 citationsA multiplex MSD assay for quantification of pertussis, tetanus, and diphtheria serum antibodies in serum and breast milk in serosurveys or vaccine studies is developed and is the first description of a multiplex assay for the quantification of pertussis, tetanus, and diphtheria antibodies in breast milk.
V. Pool, A. Tomovici, David R. Johnson et al. · 2018
47 citationsTdap and Td provide long-lasting protective immune responses against diphtheria and tetanus, and these data may inform discussion of the need for repeat Tdap booster vaccinations among adults.